secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001628280-25-024435
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026
-------------------------------------------------------------------

- Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.
- Cash and equivalents $125M at March 31, 2025; runway into 2027, extendable to 2028 by delaying new indications.
- Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa on track; topline data expected in 2026.
- Mike Heffernan appointed Chairman of the Board.
- R&D expenses $9.1M (+$7M YoY) driven by LOTUS trial; G&A $5.5M (+$2.4M YoY) on stock compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/0001628280-25-024435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025024435/avtx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-024435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer